Dimension Inx, a biofabrication company developing regenerative medical implants that repair tissues and organs, raised $3.175 million to close its Series Seed financing round. Funds will support commercial development and FDA clearance of the company’s first therapeutic implants for facial reconstruction in patients following trauma or dental malformations due to congenital defects or aging. Preclinical studies for FDA 510(k) submission are slated to begin in 2021.
Dimension Inx uses patented materials design and manufacturing to create 3D-printed implants for tissue repair and regeneration. The platform supports compositional and microstructural features not otherwise commercially feasible.
“We are incredibly fortunate to partner with investors who support our big vision and appreciate our pragmatic approach to the market, while also understanding the deep science involved in getting there,” said Dr. Caralynn Collens, M.D., Dimension Inx CEO. “We’re looking forward to advancing the science and expanding our strategic partnerships to address a much broader set of surgical applications.”
The round was led by KdT Ventures, with Better Ventures and Revolution’s Rise of the Rest Seed Fund participating.
Dr. Ramille Shah and Dr. Adam Jakus, two of Dimension Inx's co-founders. Dr. Shah is
handling a jar of Hyperelastic Bone synthetic bone biomaterial, and Dr. Jakus is
handling a 3D-printed structure (in the shape of a pelvis) made of Hyperelastic Bone.